ENANTA PHARMACEUTICALS INC (ENTA) earnings date
Feb 8, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q1 FY2027
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 42 days, typically, give or take 3 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q4 FY2026 | Mon, Nov 16, 2026 | after close | 47 | 8-K |
| Q3 FY2026 | Mon, Aug 10, 2026 | after close | 41 | 8-K |
| Q2 FY2026 | Mon, May 11, 2026 | after close | 41 | 8-K |
| Q1 FY2026 | Mon, Feb 9, 2026 | after close | 40 | 8-K |
| Q4 FY2025 | Mon, Nov 17, 2025 | after close | 48 | 8-K |
| Q3 FY2025 | Mon, Aug 11, 2025 | after close | 42 | 8-K |
| Q2 FY2025 | Mon, May 12, 2025 | after close | 42 | 8-K |
| Q1 FY2025 | Mon, Feb 10, 2025 | after close | 41 | 8-K |
What they guided beta
| Q4 FY2026 | "Completed Enrollment in LOTUS, a Phase 2b Trial of Zelicapavir in Pediatric Patients with Respiratory Syncytial Virus (RSV); Topline Data Expected in 1Q 2027" exhibit |
| Q4 FY2026 | "Initiated Dosing in RESOLVE, a Phase 2b/3 Trial of Zelicapavir in Adult Patients at High-Risk of Severe RSV Outcomes; Topline Phase 2b Data Expected in 2027" exhibit |
| Q4 FY2026 | "Topline Data from Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, Now Expected in 1Q 2027" exhibit |
| Q4 FY2026 | "Investigational New Drug (IND) Application Filing for EDP-903, an Oral, Once-Daily STAT6 Inhibitor, Now Expected in 2Q 2027" exhibit |
| Q4 FY2026 | "Cash and Marketable Securities Totaling $194.5 Million at September 30, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029 WATERTOWN, Mass., November 16, 2026 – Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2026." exhibit |
| Q3 FY2026 | "Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027" exhibit |
| Q3 FY2026 | "On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027" exhibit |
| Q3 FY2026 | "On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026" exhibit |
| Q3 FY2026 | "On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026" exhibit |
| Q3 FY2026 | "Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029 WATERTOWN, Mass., August 10, 2026 – Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ENTA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ENTA
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ENTA/"><img src="https://veritasdata.dev/embed/ENTA.svg" alt="ENTA earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ENTA/)
Script
<script async src="https://veritasdata.dev/embed/ENTA.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ENTA"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.